A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

September 13, 2020

Primary Completion Date

February 10, 2023

Study Completion Date

October 4, 2026

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Belzutifan

Oral administration

Trial Locations (48)

2109

Macquarie University ( Site 1007), Macquarie University

2610

GZA Sint Augustinus ( Site 2003), Wilrijk

3000

UZ Leuven ( Site 2001), Leuven

3128

Eastern Health - Box Hill Hospital ( Site 1003), Box Hill

3199

Peninsula Health Frankston Hospital ( Site 1001), Frankston

4000

CHU de Liege ( Site 2002), Liège

6000

Grand Hopital de Charleroi ( Site 2005), Charleroi

9000

UZ Gent ( Site 2004), Ghent

12206

New York Oncology Hematology P.C ( Site 0028), Albany

14263

Roswell Park Cancer Institute ( Site 0038), Buffalo

19111

Fox Chase Cancer Center ( Site 0026), Philadelphia

20007

Georgetown University Medical Center ( Site 0002), Washington D.C.

21237

Weinberg Cancer Institute at Franklin Square ( Site 0007), Baltimore

22031

Inova Schar Cancer Institute ( Site 0001), Fairfax

24014

Blue Ridge Cancer Care - Roanoke ( Site 0017), Roanoke

33136

Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023), Miami

37209

Urology Associates ( Site 0015), Nashville

38138

UT West Cancer Center ( Site 0032), Germantown

40207

Norton Cancer Institute - St. Matthews ( Site 0025), Louisville

57104

Sanford Cancer Center Oncology Clinic ( Site 0031), Sioux Falls

68130

Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012), Omaha

68510

Cancer Partners of Nebraska ( Site 0003), Lincoln

75390

University of Texas Southwestern Medical Center at Dallas ( Site 0004), Dallas

76508

Baylor Scott & White Medical Center - Temple ( Site 0013), Temple

84112

Huntsman Cancer Institute ( Site 0037), Salt Lake City

99336

Kadlec Clinic Hematology and Oncology ( Site 0008), Kennewick

117997

Federal state budgetary institution Russian Research Centre of radiology and nuclear medicine ( Site, Moscow

129090

City Clinical Oncology Hospital No. 1 ( Site 6004), Moscow

197758

Clinical Research Center of specialized types medical care-Oncology ( Site 6002), Saint Petersburg

Russian Scientific Center of Radiology and Surgical Technologies ( Site 6001), Saint Petersburg

3109601

Rambam Medical Center ( Site 4001), Haifa

4941492

Rabin Medical Center ( Site 4002), Petah Tikva

6423906

Sourasky Medical Center ( Site 4003), Tel Aviv

8410101

Soroka Medical Center ( Site 4004), Beersheba

115 28

"General Hospital of Athens Alexandra ( Site 1102)", Athens

12 462

Athens University Hospital ATTIKON ( Site 1100), Chaïdári

411 10

University General Hospital of Larissa ( Site 1101), Larissa

T12 DC4A

Cork University Hospital ( Site 9053), Cork

D24 NR0A

Tallaght University Hospital ( Site 9051), Dublin

6202AZ

Maastricht Universitair Medisch Centrum - MUMC ( Site 5001), Maastricht

1066 CX

Antoni van Leeuwenhoek Ziekenhuis ( Site 5003), Amsterdam

8025 AB

Isala klinieken ( Site 5002), Zwolle

3015 GD

Erasmus MC ( Site 5000), Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht ( Site 5004), Utrecht

NW3 2QG

Royal Free London NHS Foundation Trust ( Site 9003), London

W6 8RF

Imperial College Healthcare NHS Trust ( Site 9004), London

OX3 7LE

Churchill Hospital ( Site 9000), Oxford

NG5 1PB

Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 9001), Nottingham

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY